Hospital Research Teams
The Precision Cellular Therapy Laboratory
Overview
The Precision Cellular Therapy Laboratory is dedicated to advancing the understanding and effectiveness and safety of cellular therapies. Our research primarily focuses on uncovering drivers and mechanisms of resistance and toxicity that challenge the success of cellular therapies such as chimeric antigen receptor T-cell therapy and hematopoietic cell transplantation. By integrating multiomic approaches and novel computational techniques, we strive to identify and decode the biological drivers of disease resistance and adverse outcomes. Our goal is to translate these insights into more precise and safer therapeutic strategies, ultimately enhancing patient outcomes in hematologic malignancies and beyond.
Current Projects:
- Synthesizing multimodal data for prediction of CAR-T cell therapy outcome
- Uncovering genomic drivers of resistance to CAR-T cell therapy in lymphoma
- Dynamic Modeling of Cellular Therapy Toxicity
Publications
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Cordas Dos Santos DM, Tix T, Shouval R, Gafter-Gvili A, Alberge JB, Cliff ERS, Theurich S, von Bergwelt-Baildon M, Ghobrial IM, Subklewe M, Perales MA, Rejeski K.Nat Med. 2024 Jul 8. doi: 10.1038/s41591-024-03084-6. Online ahead of print.PMID: 38977912
CD19-directed CART Therapy for T cell/Histiocyte Rich Large B-cell Lymphoma. Pophali PA, Fein JA, Ahn KW, Allbee-Johnson M, Ahmed N, Awan FT, Farhan S, Grover NS, Hilal T, Iqbal M, Maakaron J, Modi D, Nasrollahi E, Schachter L, Sauter CS, Hamadani M, Herrera AF, Shouval R, Shadman M.Blood Adv. 2024 Jul 10:bloodadvances.2024013863. doi: 10.1182/bloodadvances.2024013863. Online ahead of print.PMID: 38985302
Subsequent Malignancies after CD19-Targeted Chimeric Antigen Receptor T cells in Patients with Lymphoma. Lorenc R*, Shouval R*, Flynn JR, Devlin SM, Saldia A, De Abia AL, De Lapuerta MC, Tomas AA, Cassanello G, Leslie LA, Rejeski K, Lin RJ, Scordo M, Shah GL, Palomba ML, Salles G, Park J, Giralt SA, Perales MA, Ip A, Dahi PB.Transplant Cell Ther. 2024 Jul 5:S2666-6367(24)00491-3. doi: 10.1016/j.jtct.2024.06.027. Online ahead of print.PMID: 38972512 *Equal contribution
Conditioning Regimens are Associated with Distinct Patterns of Microbiota Injury in Allogeneic Hematopoietic Cell Transplantation. Shouval R, Waters NR, Gomes ALC, Zuanelli Brambilla C, Fei T, Devlin SM, Nguyen CL, Markey KA, Dai A, Slingerland JB, Clurman AG, Fontana E, Amoretti LA, Wright RJ, Hohl TM, Taur Y, Sung AD, Weber D, Hashimoto D, Teshima T, Chao NJ, Holler E, Scordo M, Giralt SA, Perales MA, Peled JU, van den Brink MRM.Clin Cancer Res. 2023 Jan 4;29(1):165-173. doi: 10.1158/1078-0432.CCR-22-1254.
Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: Incidence, risk factors and biomarker profile. Shouval R, Goldman A, Flynn JR, El-Moghraby A, Rehman M, Devlin SM, Corona M, Landego I, Lin RJ, Scordo M, Raj SS, Giralt SA, Palomba ML, Dahi PB, Walji M, Salles G, Nath K, Geyer MB, Park JH, Fein JA, Kosmidou I, Shah GL, Liu JE, Perales MA, Mahmood SS.Br J Haematol. 2024 May 12. doi: 10.1111/bjh.19497. Online ahead of print.PMID: 38735683
People
- MD: Technion, Israel Institute of Technology | Haifa, Israel
- PhD: Bar Ilan University | Ramat Gan, Israel
Members
Alumni
Affiliations
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
General Opportunities
For inquiries about graduate student rotations, postdoctoral fellowships, medical research fellowships, or technician positions, please contact [email protected].